NCT04575818View on ClinicalTrials.gov

A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059

PHASE1TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

April 8, 2021

Study Completion Date

April 8, 2021

Conditions
Healthy
Interventions
DRUG

GLPG4059 oral suspension

GLPG4059 for oral administration

DRUG

Placebo

Placebo oral suspension

DRUG

GLPG4059 tablet

GLPG4059 for oral administration

Trial Locations (1)

9728

PRA Health Sciences, Groningen

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY